NeuroMetrix, Inc. (Nasdaq: NURO)
NeuroMetrix is a commercial stage company that was founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and Technology.
The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® Fibromyalgia is a wearable neurostimulation device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity.
The Company is based in Woburn, MA.
Our mission is to improve health through neurotechnology
NeuroMetrix is driven to solve unmet healthcare needs in the worldwide neurology and pain markets. The company’s expertise in neurotechnology is applied to create meaningful innovation. We develop novel medical devices that utilize a proprietary consumable. The majority of our revenue is generated by aftermarket sales of these consumables.